A research team from the Dasman Diabetes Institute, established by the Kuwait Foundation for the Advancement of Sciences (KFAS), has published a groundbreaking study in the Journal of Cellular and Molecular Medicine.
The study opens new avenues in type 2 diabetes research by uncovering how the transcription factor KLF15 interacts with DNA at the atomic level.
Led by Dr. Anwar Mohammed, the study employed cutting-edge artificial intelligence tools, particularly the AlphaFold 3.0 platform, to accurately predict the 3D structure of the interaction between the KLF15 protein and a key genetic element, reports Al-Jarida daily.
This discovery could pave the way for the development of next-generation drugs that precisely target this molecular interaction.
“This study marks a significant step toward understanding the molecular mechanisms through which KLF15 regulates glucose metabolism,” said Dr. Anwar Mohammed, the lead researcher. “Our goal is to develop more precise and effective pharmaceutical treatments for diabetes.”
He added that the research utilized an integrated computational approach combining molecular modeling, dynamic simulation, and energy analysis. This enabled the team to pinpoint four critical sites on the KLF15 protein that could serve as starting points for novel drug development.
The study was supported by KFAS and highlights Kuwait’s growing role in the global biomedical research landscape. It reflects the country’s commitment to precision medicine and the application of artificial intelligence in tackling chronic diseases like diabetes that pose major public health challenges.
